

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.

Press Release


STADA's continued, resilient growth leads to record earnings in Q1

- Group adjusted constant-currency (cc) revenues rise by 4% and adjusted cc EBITDA improves by 5% to a record €245 million in first quarter of 2025
- Specialty adjusted cc revenues climb by 22%, driven by strong market penetration of biosimilars, especially Uzpruvo (ustekinumab), as well as growing patient numbers for innovative medicines like Kinpeygo and Lecigon
- STADA CEO Peter Goldschmidt: "Our resilient three-segment business model delivered again in the first quarter of this year. The diversified portfolio and broad footprint enabled us to overcome geopolitical challenges and market uncertainty. With limited exposure to the US market, to tariff reforms and to currency fluctuations, I am very confident that we will continue our strong growth journey also in 2025."

Bad Vilbel, Germany – 3 June 2025 - STADA, a leading healthcare company in Consumer Healthcare, Generics and Specialty pharmaceuticals, achieved record earnings on revenues growth in its financial first quarter ended 31 March 2025.

Group adjusted, constant-currency (cc) revenues advanced by 4% on an organic basis to €1.081 billion. This development was driven by a double-digit increase in revenues by the Group's Specialty segment, aided by further market penetration with the Uzpruvo (ustekinumab) biosimilar launched in Europe from July 2024.

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au



Adjusted cc earnings before interest, tax, depreciation and amortization (EBITDA) improved by 5% to €245 million, a historic high against a strong prior-year base.

“Our resilient business model delivered again in the first quarter of this year, as our diversified portfolio and broad footprint enabled us to overcome geopolitical challenges and market uncertainty,” commented STADA’s CEO, Peter Goldschmidt. “Our symbiotic three-segment strategy gives us a broad basis for growth, with no dependence on individual products or countries.”

Specialty grows by 22% on launches and in-market uptake


A 22% increase in first-quarter Specialty adjusted cc revenues was largely attributable to a strong market performance and penetration of the Uzpruvo (ustekinumab) biosimilar launched from July 2024. This was reinforced by continued broad-based growth of in-market biosimilars and the introduction of bosutinib, nilotinib and paliperidone, along with further local launches and increasing patient uptake of the innovative Kinpeygo (modified-release budesonide) nephrology brand through STADA’s strong marketing and sales capabilities.

Generics adjusted cc revenues moved ahead by 1% versus a strong prior-year quarter influenced by the timing tender effects in Germany. Outside of Germany, Generics revenues in other countries increased in high single digits during the 2025 first quarter, driven by contributions from recent launches including dabigatran and rivaroxaban.

Consumer Healthcare revenues were more or less stable at -1% compared to Q1 in 2024 amid a weak cough and cold season and trade stock reductions by market participants. In-market, sell-out performance remained very strong, with a mid-single digit increase of adjusted cc Consumer Healthcare products other than cough, cold and allergy products.

“Gross margin improvements and our rigor on return-on-investment from marketing and sales activities enabled an expansion of our adjusted cc EBITDA margin to 22.7% during the

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au



first quarter,” commented CFO Boris Döbler. “In addition to our record high EBITDA, our effective capital management enabled us to achieve a strong core free cash flow of €197 million.”


Sustainable growth remains a key priority, as detailed in the Group’s recently published 2024 Sustainability Report, which describes numerous environmental, social and governance (ESG) initiatives that have seen independent agency Sustainalytics rank STADA among the top 3% of its direct pharma peers.

“Capacity utilization at our new state-of-the-art supply chain hub in Romania is ramping up, while 22 business-development and licensing deals signed during the first quarter will support our portfolio acceleration for our commercial platform spanning more than 40 countries,” Goldschmidt asserted. “With limited exposure to the US market, to tariff reforms and currency fluctuations,” Goldschmidt concluded, “I am confident that we will maintain our strong growth journey also in 2025.”

Disclaimer

Neither this communication nor the publication in which it is contained is for publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America, including its territories and possessions, any state of the United States and the District of Columbia (the “United States”). This communication is not and does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, Australia, Canada or Japan, or any other jurisdiction in which such offer may be restricted or unlawful.

Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold, subscribed, used, pledged, resold, allotted, delivered or otherwise transferred, directly or indirectly, in or into the United States absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements under the Securities Act, and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States.

**About STADA Arzneimittel AG**

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2024, STADA achieved group sales of € 4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 886 million. As of 31 December 2024, STADA employed 11,649 people worldwide.

Additional information for journalists

STADA Arzneimittel AG - Media Relations

Stadastrasse 2-18

61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

E-Mail: press@stada.de

Or visit us via our website at <https://www.stada.com/media/newsroom>

Follow [@StadaGroup](#) on LinkedIn

Additional information for capital market participants

STADA Arzneimittel AG - Investor & Creditor Relations

Stadastrasse 2-18

61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-4689

Fax: +49 (0) 6101 603-215

E-mail: ir@stada.de

Or visit us via our website at <https://www.stada.com/investor-relations/>

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler

Chairman of the Supervisory Board: Dr. Günter von Au